Imugene Ltd
IMU
Company Profile
Business description
Imugene Ltd specializes in a clinical-stage immuno-oncology company. Its products include HER-Vaxx, PD1-Vaxx, CF33 and CF33 CD19. HER-Vaxx is a proprietary HER2 +ve cancer vaccine that stimulates a polyclonal antibody response to HER2/neu. The company is also developing B-cell peptide cancer vaccines and therapeutics. Its only operating segment is the Research and Development of oncolytic immunotherapies.
Contact
4-6 Bligh Street
Suite 12.01, Level 12
SydneyNSW2000
AUSSector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2025
Employees
5
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,385.50 | 16.20 | 0.19% |
| CAC 40 | 7,696.92 | 31.01 | -0.40% |
| DAX 40 | 23,249.65 | 94.89 | -0.41% |
| Dow JONES (US) | 40,829.00 | 389.83 | -0.95% |
| FTSE 100 | 8,597.42 | 1.07 | 0.01% |
| HKSE | 23,054.76 | 392.05 | 1.73% |
| NASDAQ | 17,689.66 | 154.58 | -0.87% |
| Nikkei 225 | 36,777.88 | 52.81 | -0.14% |
| NZX 50 Index | 12,459.77 | 38.68 | 0.31% |
| S&P 500 | 5,606.91 | 43.47 | -0.77% |
| S&P/ASX 200 | 8,166.70 | 15.30 | 0.19% |
| SSE Composite Index | 3,335.50 | 19.39 | 0.58% |